Clinical trial · Interventional
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase I trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating women who have stage III or stage IV endometrial cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Adenocarcinoma | Endometrial Adenocarcinoma | CURATED_BROADER | 0.80 |
| Endometrial Clear Cell Adenocarcinoma | Endometrial Clear Cell Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Endometrial Serous Adenocarcinoma | Endometrial Serous Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Stage III Uterine Corpus Cancer | Malignant Uterine Corpus Neoplasm | CURATED_BROADER | 0.78 |
| Stage IV Uterine Corpus Cancer | Malignant Uterine Corpus Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| Doxorubicin Hydrochloride | Drug | Doxorubicin | ALIAS |
| Radiation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment (doxorubicin, cisplatin, radiation therapy)
- description
- Patients receive doxorubicin IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 3 courses. Patients then undergo whole abdominal radiotherapy 5 days a week for 4-6 weeks.
- interventionNames
- Drug: Doxorubicin Hydrochloride
- Drug: Cisplatin
- Radiation: Radiation Therapy
Primary outcomes (4)
- measure
- Number of patients completing the prescribed therapy
- timeFrame
- Up to 9 weeks
- measure
- Frequency and severity of acute adverse effects as assessed by CTEP CTC version 2.0
- timeFrame
- 3 weeks
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed endometrial cancer including 1 of the following subtypes: * Clear cell carcinoma * Serous papillary carcinoma * Endometrioid adenocarcinoma * Stage III or IV disease * Positive adnexa * Metastases to serosa, bowel mucosa, abdomen * Positive pelvic or paraaortic nodes * Positive pelvic washings or vaginal involvement within the radiation port * Tumor must be surgically reduced to 2 cm or less within 8 weeks of study entry * Must have had a hysterectomy and bilateral salpingo oophorectomy * No recurrent disease * No distant metastases outside of abdominopelvic area, including: * Parenchymal liver metastases * Lung metastases * Positive inguinal lymph nodes * Positive supraclavicular nodes * Pleural effusion with malignant cytology * Performance status - GOG 0-2 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * SGOT and alkaline phosphatase no greater than 3 times ULN * Creatinine no greater than ULN * Cardiac ejection fraction greater than 50% * No other prior or concurrent malignancy within the past 5 years except nonmelanoma skin cancer * No prior chemotherapy * No prior pelvic or abdominal radiotherapy * No prior radiotherapy for other prior malignancy
References
Publications (0)
Data not yet available